Login
Navigate Fool.com
Will AUXL beat
the market?
Community Rating: 3 Stars: Appealing

25.52 0.73 (2.94%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $25.36
Previous Close $24.79
Daily Range $25.00 - $25.65
52-Week Range $13.87 - $32.89
Market Cap $1.3B
P/E Ratio -67.00
Dividend (Yield) $0.00 (0.0%)
Volume 290,296
Average Daily Volume 1,313,834
Current FY EPS $0.60

How do you think AUXL
will perform against the market?

Top AUXL Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted May 28, 2010

Auxilium has been selling off lately likely due to pessimism about the launch of Xiaflex. Do I have an inside track on the issues of usage and reimbursement? Unfortunately not. But I don't believe the … More

0 Replies Reply Report this Post
 

alvinbentley (< 20)
Submitted April 29, 2008

Do any investors out there know anything about Dupuytren's contracture? It is not very common. Most patients who need intervention would be referred to an orthopedic surgeon. If Xiaflex were actual … More

1 Replies Reply Report this Post

News & Commentary

Today's Top Biotech Stories: Ampio Pharmaceuticals, Auxilium Pharmaceuticals, Bayer, and Medivation

Today's top stories in healthcare and biotech.

Biotech Auxilium Boosts Position In Men's Health Care

Earnings Reaction History: Auxilium Pharmaceuticals Inc., 54.5% Follow-Through Indicator, 10.3% Sens

Earnings Reaction History: Auxilium Pharmaceuticals Inc., 54.5% Follow-Through Indicator, 10.3% Sensitive

VIVUS' Q4 Loss Shrinks 70% as Licensing Revenue Soars

VIVUS delivers a much smaller quarterly loss on tighter cost controls and soaring licensing revenue despite relatively slow-growing sales of lead drug Qsymia.

VIVUS, Inc. Earnings: What to Expect Monday

Can the obesity-drug maker get out of its slump and start delivering for shareholders?

A Not-So Fat 2013 for This Obesity-Drug Maker

VIVUS struggled in 2013. To compete with Arena Pharmaceuticals and Orexigen in 2014, the biotech needs a marketing partner.

New ED Drug: Analysis of Vivus’s Prospects

Stock Upgrades: 3M Gets Out of a Sticky Situation

This Week in Biotech: Part 1

With 11 major biotech events this week, Part 1 of this two-part series looks at four FDA influenced actions of the week, including two fresh drug approvals, as well as a monster of a collaborative deal that could be worth billions for one lucky company!

Why Pacific Sunwear, Auxilium Pharmaceuticals, and Gray Television Are Today's 3 Best Stocks

The S&P 500 breaks its five-day losing streak on strong jobs data but still takes a back seat to the double-digit gains for Pacific Sunwear, Auxilium Pharmaceuticals, and Gray Television.

See More AUXL News...

Sector

Healthcare

Industry

Drugs

Auxilium Pharmaceuticals, Inc. (AUXL) Description

A specialty biopharmaceutical company with a focus on developing and marketing products to urologists, endocrinologists, orthopedists and select primary care physicians. Website: http://www.auxilium.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks